CD27 antibody (PE/Dazzle™ 594)

Catalog No. ABIN2659697

This anti-CD27 antibody is a Mouse Monoclonal antibody detecting CD27 in FACS and IP. Suitable for Human.

Quick Overview for CD27 antibody (PE/Dazzle™ 594) (ABIN2659697)

Target: CD27 (CD27 Molecule (CD27))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD27 antibody is conjugated to PE/Dazzle™ 594

Application: Flow Cytometry (FACS), Immunoprecipitation (IP)

Clone: M-T271

Product Details anti-CD27 Antibody (PE/Dazzle™ 594)

Cross-Reactivity: Baboon, Cynomolgus, Rhesus Monkey

Purification: The antibody was purified by affinity chromatography and conjugated with PE/Dazzle™ 594 under optimal conditions. The solution is free of unconjugated PE/Dazzle™ 594 and unconjugated antibody.

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for CD27

Target: CD27 (CD27 Molecule (CD27))

Alternative Name: CD27

Background: CD27 is a 50-55 kD type I membrane protein also known as S152 and T14. It is a lymphocyte-specific member of the TNF-receptor superfamily. CD27 is expressed on medullary thymocytes, virtually all mature T cells, some B cells, and NK cells. CD27 binds to CD70, and plays a role in costimulation of T cell activation and regulation of B cell differentiation and proliferation. The cytoplasmic domains of CD27 have also been shown to interact with TRAF2 and TRAF5 to elicit NF-κB and SAPK/JNK activation.

Pathways: Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints